
Curriculum vitae



Emmanuel E. Baetge

Designated Head of the Nestlé Institute of Health Sciences



Professor Emmanuel E. Baetge has been appointed to head up the new Nestlé Institute of Health Sciences, to be located on the premises of the Swiss Federal Institute of Technology in Lausanne (EPFL).

The new Institute, which will form part of Nestlé's extensive R&D network, is to play the lead role in breaking new scientific ground in the field of personalised health science nutrition to prevent and treat acute and chronic diseases.

Emmanuel E. Baetge is one of the world's leading scientists researching the use of stem cells to cure Type I diabetes and he has an international reputation as an authority in the fields of neuroscience, gene therapy and metabolic diseases.

Until now Emmanuel E. Baetge has been Senior Vice President and Chief Scientific Officer of ViaCyte in San Diego, California, heading its human stem cell project, the leading programme in stem cell derived pancreatic islets for diabetes. He joined ViaCyte, formerly known as Cythera/Novocell, in May 2001. In that time he has built a scientific and patent portfolio from the ground up, creating the foremost stem cell therapy company in diabetes. Since 2000, the company has raised more than USD 70 million in grants and investments.

Prior to joining ViaCyte, Emmanuel E. Baetge was Chief Scientific Officer at Modex Therapeutics in Lausanne, where he worked between 1997 and 2001. Modex developed a personalised adult stem cell therapy product for the treatment of chronic ulcers. Emmanuel E. Baetge led the scientific component of its successful Swiss New Market IPO, raising CHF 83 million.

Before Modex, Emmanuel E. Baetge held management positions at CytoTherapeutics Inc. (from 1992-1997) and Bristol-Myers Squibb (from 1987 to 1992). He holds a Ph.D in molecular neurobiology from Cornell University and carried out postdoctoral work at Cornell University and the Howard Hughes Medical Institute in Seattle, Washington.

Professor Emmanuel E. Baetge has published ground breaking work in the fields of cell and gene therapy in leading international journals worldwide. He has also authored a wide range of issued patents on cell, gene and device technologies.
